Relapses in multiple sclerosis might be a bigger problem than previously thought.
The burden of moderate-to-severe relapses in multiple sclerosis (MS) patients is underappreciated, according to a study sponsored by the pharmaceutical company Mallinckrodt.
Researchers discussed the findings at the American Academy of Neurology’s 69th annual meeting in Boston, April 22-28. The title of the presentation was “The Economic Burden Of Moderate-To-Severe Multiple Sclerosis Relapse In The United States: Findings From A Systematic Literature Review.”
A study in 2003 put the three-month cost of a moderate-intensity relapse at $1,847 and a high-intensity one at $12,870. In 2016, those costs would be equivalent to $3,092 and $21,544.
Read full article: Multiple Sclerosis Relapse Burden Is Underappreciated, Study Contends
|Read Full Article: Multiple Sclerosis Relapse Burden Is Underappreciated, Study Contends|